Current chemotherapies for recurrent/metastatic head and neck cancer
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Pharmacology (medical),Pharmacology,Oncology
Reference46 articles.
1. Cancer statistics, 2006.;Jemal;CA Cancer J Clin,2006
2. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.;Forastiere;J Clin Oncol,1992
3. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic andor recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.;Schornagel;J Clin Oncol,1995
4. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastaticrecurrent head and neck cancer: an Eastern Cooperative Oncology Group study.;Burtness;J Clin Oncol,2005
5. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.;Jacobs;J Clin Oncol,1992
Cited by 37 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The application of mesoporous silica nanoparticles as a drug delivery vehicle in oral disease treatment;Frontiers in Cellular and Infection Microbiology;2023-02-14
2. Squamous Cell Carcinoma of Head and Neck;Clinical Diagnosis and Management of Squamous Cell Carcinoma;2023-01-04
3. CDH3 is associated with poor prognosis by promoting the malignancy and chemoresistance in oral squamous cell carcinoma;Asian Journal of Surgery;2022-12
4. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials;World Journal of Clinical Oncology;2022-05-24
5. HPRT1 Promotes Chemoresistance in Oral Squamous Cell Carcinoma via Activating MMP1/PI3K/Akt Signaling Pathway;Cancers;2022-02-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3